DOWNLOAD CATALOGUE

Our Company
- Our Corporate Structure
Our Science
- Innovative Generics (Gx+)
  - Our Innovation Strategy
  - Our Innovative Projects
- Pharma Manufacturing & QC
Our Products & Services
- Our Products in Greece
- Our Diagnostics

Your Career

$0.00

✕

MARKET AVAILABILITY

Shop

Home
In Greece
Dulsevia®

< Back to catalogue

D3ZAC®

15 Ιουλίου, 2026

Everolimus/Pharmazac

15 Ιουλίου, 2026

Dulsevia®

PHARMAZAC

Dulsevia®

Duloxetine | Antidepressant | CNS

Market availability: In Greece

DULSEVIA GR.CAP 30MG/CAP BTx30 CAPS

DULSEVIA GR.CAP 60MG/CAP BTx30 CAPS

Share

Περιγραφή

DULSEVIA GR.CAP 30MG/CAP BTx30 CAPS

DULSEVIA GR.CAP 60MG/CAP BTx30 CAPS

Σχετικά προϊόντα

Aromestan®
Abiraterone/Pharmazac
Everolimus/Pharmazac
Aregalu®

PHARMAZAC

Top Products

THERAPEUTIC AREA -

Allergy
Anesthesiology
Cardiology / Diagnostic imaging
Cardiovascular
Cardiovascular / Antithrombotic therapy
Cardiovascular / Cardiology
Cardiovascular / Dyslipidemia
Cardiovascular / Hypertension
Endocrinology
Endocrinology / Bone metabolism
Infectious diseases
Iron deficiency
Musculoskeletal disorders
Nephrology
Neurology
Neurology / Alzheimer's disease
Neurology / Epilepsy
Neurology / Peripheral neuropathy
Obstetrics
Oncology
Oncology / Endocrinology
Oncology / Hematology
Oncology / Urology
Psychiatry
Psychiatry / Neurology
Radiology / Diagnostic imaging
Radiology / MRI contrast enhancement

PHARMACOLOGICAL CLASS +

BUSINESS UNIT +

CNS
Contrast Media Agents
Oncology
Primary Care
Radiopharmaceutical
Teriflunomide

ACTIVE SUBSTANCE +

PRESCRIPTION REQUIREMENT +

OTC (over-the-counter)
Rx (prescription required)

Follow us

Headquarters, Pharmaceutical Manufacturing Site & R&D Laboratory

1, Anastasiou Zaroliagki & 6, Dimitriou Lamprou Str.
GR-19001 Keratea – Attica
Greece
Tel. +30 210 3418889-97
Fax +30 210 8661262

Radiopharmaceutical Manufacturing Site

Naousis 31
Athens 104 47,
Votanikos Greece
Tel. +30 210 3418889-97
Fax +30 210 8661262

P. Patron Germanou 27
Thessaloniki 546 42, Greece
Tel. +30 2310 933534
Fax +30 2310 933524

Report of Adverse Events

For any adverse events report contact the Pharmaco-vigilance or Medical information department:
Τel : +30 210 3259365 (24/7 line ),
Fax: +30 210 3259368,
email: pv@creativephs.com

Corporate Statements/Publications

Financial Statements
Media Material
Corporate Presentation
PDF

© 2026 | All Rights Reserved

Web Design & Development by Generation Y

$0.00

No translations available for this page

Σύνδεση

Όνομα χρήστη ή email *

Συνθηματικό *

Να με θυμάσαι

Χάσατε το συνθηματικό πρόσβασής σας;